The FDA granted approval of axicabtagene ciloleucel (YESCARTA) on October 25, 2017, two months following the approval of tisagenlecleucel (KYMRIAH) – both are anti-CD19-directed CAR T (chimeric antigen receptor T-cell) therapies that employ re-programmed autologous T-cells to fight cancer: Continue reading
Tag Archives: Chimeric Antigen Receptor T-cells
Gene-edited donor T-cells save baby with incurable leukemia
An experimental therapy made of genetically-modified donor T-cells cured a baby with incurable leukemia: Continue reading
Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming
Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment. Continue reading
Lentiviral Vectors for Gene Transfection in CAR T-cell Therapy
Novartis entered into a $90 MM deal with Oxford Biomedica for use of its lentiviral vectors with its CAR (chimeric antigen receptor) modified T-cell product, CTL019, being developed with researchers at UPENN. Continue reading